ArticleBMC infectious diseases2026
Hepatitis B coinfection and awareness among patients with active tuberculosis in Georgia: a cross-sectional study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPatients with TB disease in Georgia are not routinely tested for HBV and the prevalence of chronic HBV among TB patients is unknown. We aimed to assess the prevalence of HBV coinfection and immunity among persons with TB in Georgia and evaluate their HBV-related knowledge and attitudes toward vaccination.
methodsWe conducted a cross-sectional study among persons with active TB disease at the National Center for Tuberculosis and Lung Diseases in Georgia from September 20, 2024 to February 20, 2025. Participants underwent serologic testing (HBsAg, anti-HBs, anti-HBc) and completed a questionnaire on HBV knowledge, vaccination history, and willingness to vaccinate.
resultsWe enrolled 110 participants (median age = 44.0, IQR:35.0-56.3), of which 63.6% were male. Four participants (3.6%) were HBsAg positive. HBV test results showed 14 (12.7%) had past HBV infection with anti-HBc+/anti-HBs+, and 7 (6.4%) had isolated anti-HBc positivity (anti-HBc+/anti-HBs-). Another seven (6.4%) had vaccine-induced immunity (anti-HBc-/anti-HBs+), and 82 (74.5%) were susceptible to HBV infection. While 74.5% reported having heard of HBV, only 50.0% correctly identified transmission routes. Only 16 patients (14.5%) were willing to receive vaccination. Among those unwilling, the main barriers were concerns about vaccine safety (34.9%), effectiveness (23.3%), and perceived infection risk (20.9%). Participants aged ≤ 40 years were significantly more likely to be aware of HBV compared to those over 40 (OR=3.39, 95% CI: 1.25-9.20).
conclusionTB-HBV coinfection observed in this study suggests that routine HBV screening among TB patients in Georgia may be beneficial. Low vaccination coverage and limited knowledge highlight the importance of integrating HBV education and vaccination into TB programs to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.